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Regenerative medicine is a site for opposing forces of gatekeeping and innovation. 
This applies both to regulation of market entry and to clinical adoption. Key gateways 
include the EU’s Advanced Therapy Medicinal Products Regulation, technology 
assessment body NICE and commissioning/service contractor National Health Service 
England. The paper maps recent gatekeeping flexibilities, describing the range of 
gateways to market and healthcare adoption seen as alternatives to mainstream 
routes. The initiatives range from exemptions in pharmaceutical and ATMP regulations, 
through ‘adaptive pathways’ and ‘risk-based’ approaches, to special designation for 
promising innovation, value-based assessment and commissioner developments. 
Future developments are considered in the UK’s ‘accelerated access review’. Caution 
is urged in assessing the impact of these gateway flexibilities and their market and 
public health implications.
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Major international policy developments in 
pharmaceuticals are aimed at accelerating 
the innovation and patient access process 
for new drugs. One important development 
is the New Drugs Paradigms (NEWDIGs) 
initiative, started in 2010 and moderated 
by the MIT Center for Biomedical Innova-
tion (MA, USA). This is a forum for co-
ordinating and exploring a shift from the 
dominant binary yes/no market approval 
decision-making system to a more flex-
ible, stratified, conditional approach. Recent 
developments of both in the US FDA and 
EMA are linked partly to the NEWDIGs 
initiative, which also involves the UK Medi-
cines and Healthcare products Regulatory 
Authority (MHRA), Health Canada and the 
Singapore Health Services Authority as well 
as sponsors, health technology assessment 
organizations, reimbursers/payers, patient 
associations and academics. It is aimed “on 
enhancing the capacity of the global bio-
medical innovation system to reliably and 
sustainably deliver new, better, affordable 
therapeutics to the right patients faster” [1], a 
ringing endorsement of current governments’ 
political ‘innovation’ agendas. The pharma-
ceuticals policy arena is also shaped by mas-
sive policy actions such as the Innovative 
Medicines Initiative (IMI) which is Europe’s 
largest public–private enterprise, aimed at 
accelerating the development of safer and 
improved medicines. IMI is a joint undertak-
ing between the EU and the pharmaceutical 
industry association EFPIA and supports 
collaborative research projects and networks 
across industry and academia (funded at 
GB£3.3 billion in the period 2014–2024 [2]).
In this context, the last few years have seen 
a major set of policy initiatives and actions to 
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boost the UK’s regenerative medicine activity for both 
‘health’ and ‘wealth’ objectives, including the 2011 
Life Sciences Strategy and the 2013 House of Lords 
report on regenerative medicine [3] which proposed a 
wide range of investments and infrastructural devel-
opments specifically to promote regenerative medicine 
as a sector in which the UK would excel on the world 
stage. In the UK, a research report following on from 
the House of Lords’ recommendations examined per-
ceived requirements to facilitate commercialization, 
funding and reimbursement [4]. The UK’s ‘Innovate 
UK’ and Knowledge Transfer Network are also highly 
active in promoting innovation partnerships in the 
regenerative medicine field. Furthermore, at the time 
of writing the UK government is sponsoring a wide-
ranging, consultation-based review of ‘accelerated 
access’ to medicines, devices and diagnostics [5] – this 
is discussed in the concluding section of this article, 
but it is worth noting at this point that regulatory 
and reimbursement ‘flexibilities’ are one of the key 
concepts of the review.
In considering the emergence into the market-
place and healthcare practice of regenerative medi-
cine products, a complex and sometimes baffling 
range of pathways, routes, hurdles and so on present 
themselves, so there is a need to understand and keep 
abreast of these policy-related developments, which 
continually evolve. Broadly speaking, two types of 
‘gateways’ present themselves, and each of these types 
has a range of different and evolving features, which 
must be understood and negotiated in order for prod-
ucts to have a chance of clinical translation to reach 
the bedside. In other words, in order to reach and 
pass through these evolving gateways, a number of 
different routes might in theory be taken and these 
routes recently show signs of increasing flexibility 
under pressure from the powerful biomedical innova-
tion agendas. It is important to describe and assess the 
impact of the gateway flexibilities, which is what this 
discussion sets out to do.
First, the UK’s legal regulatory activity in the field 
of regenerative medicine is conditioned by its posi-
tion in the EU and especially, though not exclusively, 
the Advanced Therapy Medicinal Products Regula-
tion of 2007. Second, the UK’s (England’s) public 
healthcare adoption activity is undertaken notably 
by technology assessment-based policy body NICE 
and commissioning/service contractor NHS England. 
Both gatekeeping arenas are the site of a range of con-
tests about whether, and if so, how, regenerative medi-
cal technologies might be accorded special treatment, 
and might fall under any of the range of regulatory 
and reimbursement flexibilities that are currently being 
developed.
Gateways to regenerative medicine 
marketplaces
The last decade has seen the development in Europe 
of a number of regulatory policy initiatives, including 
some novel gateways for biomedical innovation, that 
can be seen as relaxations by gatekeeping actors, under 
specific conditions, of the basic regulatory frameworks, 
infrastructures and dominant technology assessment 
gatekeeping regimes. This trend appears to be increas-
ing as different regimes and their gatekeepers struggle 
with the dilemmas of innovation and potential health 
benefit that regenerative medicine and its proponents 
raise. There are signs that developers and producers of 
regenerative medicine products are seeking and choos-
ing nonmainstream gateways to market in preference 
to central pathways. This leads us to ask: in what sense 
might regenerative medicine or cell therapy be framed 
and defined in market regulation and healthcare sys-
tem innovation as a special sector or zone deserving of 
its own gatekeeping conventions, its own gateways to 
markets and routes to health system/clinical adoption 
and support systems?
This article analyses current and recent trends in 
terms of the tension between existing, inherited regu-
latory domains and standards on the one hand [6], set 
against counter movements of ‘exceptionalism’ and 
‘exemptionalism’ on the other. It is argued that there is 
a trend in formal regulation to create exceptions to the 
rules of entry to the regenerative medicine marketplace 
and healthcare systems through various exemptions, 
exceptions and conditional alternative gateways to 
established paradigms, noting that this flexibility var-
ies across different jurisdictions. Some of these appar-
ent relaxations are enshrined in pharmaceutical law 
and thus apply to products more broadly than regen-
erative medicines, and some are more specifically tai-
lored. But it is further argued that, although the overall 
effect is one of somewhat hybrid, imbalanced frame-
works, it would be easy to overestimate the extent of 
these developments. In concluding reasons are offered 
why this is so.
Market access gateways for regenerative medicine 
products in the UK are institutionalized mainly via 
EU pharmaceutical or ‘advanced therapy’ regimes and 
their implementation in national authorities.
Pharmaceutical legislation in the EU already con-
tains some notable gateways to market, aside from the 
mainstream centralized market authorization routes. 
Applicable to pharmaceutical products, three main 
‘licensing flexibilities’ intended to improve develop-
ers’ incentives have already been introduced, and have 
been summarized by Mittra et al. [7]. First, is condi-
tional approval – essentially a leap frogging of Phase III 
trials and launching a Phase IV study once a product 
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has been placed on the market. Proponents argue that 
this might speed up bench to bedside translation by 
approving technologies with less than complete safety 
and efficacy data. The procedure is allowable when 
there is a complete pharmaceutical and preclinical data 
package and an almost complete set of clinical data, if it 
is considered reasonably likely that the remaining data 
will be collected in a short time frame. To qualify, a 
product must be intended for treatment, prevention or 
diagnosis of a seriously debilitating or life-threatening 
disease; have designated orphan status or be intended 
for use in emergency situations, responding to Euro-
pean Community or WHO recognized unmet medi-
cal needs. Immediate availability is likely to outweigh 
the product’s risks. Conditional marketing authoriza-
tions (MAs) must be renewed annually. It is notable 
that 10–20% of all drug approvals are now conditional 
MAs. Second, exceptional circumstances licensing is 
available when comprehensive data could never be pro-
vided, for example because the disease is too rare, the 
scientific knowledge is too limited or because of ethi-
cal issues such as constraint on submitting seriously ill 
patients to extensive tests. Third, accelerated assess-
ment is designed in principle to meet the expectations 
of patients and to take account of the rapid progress 
of scientific innovative and new therapies. It applies to 
products where there exists a strong case from public 
health benefit and therapeutic innovation perspectives. 
Application for an accelerated assessment procedure 
must justify itself on these grounds. The EMA’s Com-
mittee for Medicinal Products for Human Use makes 
a decision based on the justifications presented and 
recommendations of independent rapporteurs, and the 
normal criteria of quality, safety and efficacy apply.
Where regenerative products are deemed to be phar-
maceuticals or advanced therapy medicinal products 
(ATMPs – see below), these alternative gateways to 
market may apply. These licensing flexibilities, which 
are drafted within the pharmaceutical legislation, are 
now being recast in terms of a broader movement 
toward so-called ‘adaptive’ approaches. In March 2014 
the EMA launched an ‘adaptive licensing’ program, 
inviting companies to participate in a pilot project [8]. 
However, in 2013 the European Commission had 
stated that it was not convinced that adaptive licens-
ing per se was the best way forward [8]. The European 
Commission’s IMI initiative is currently attempting to 
clarify and consolidate these and other apparent reg-
ulatory easings under the umbrella concept of medi-
cines adaptive pathways to patients (MAPPS). EMA’s 
Eichler has preferred to redefine this initiative as ‘adap-
tive pathways’, indicating a less legally based and softer, 
provisional approach to flexible gatekeeping that argu-
ably lessens the financial risk for producers [9]. Thus 
EMA’s intended approach does not create new regula-
tory tools, but aims at: “increasing awareness and opti-
mizing the use of all tools and flexibilities within the 
existing regulatory framework” [10]. Notably, it may 
integrate a number of elements such as adaptive clini-
cal trial design, patient-centric benefit/risk assessments 
and the continuous evaluation of a therapy as new evi-
dence ‘including real-world evidence’ (e.g., data from 
a registry) becomes available [10]. Interestingly in the 
context of debate about the role of consumer/patient 
demand for therapies, the initiative includes an 
acknowledgment of patient access issues as part of a life 
cycle approach to the innovation process. The expected 
impact would be: “a comprehensive plan of develop-
ment and exploitation of tools, methodologies, infra-
structures that will allow changes in R&D, regulatory 
and medical practice to enable early patient access to 
innovative prevention and treatment options” [11].
It is notable that many of the initiatives noted 
above, including adaptive pathways and conditional 
approval, apply to medicines for rare diseases and are 
seen as part of ‘compassionate use’ programs, the drugs 
in question being accorded ‘orphan’ status in prac-
tice [12]. It is clear that the ‘orphan’ route is applicable 
to, and indeed sought by, many of the regenerative 
medicine drug products currently under development 
for relatively small numbers of patients. Alongside 
these developments in pharmaceutical regulation, on 
13 November 2007, the EU had adopted the new regu-
lation for medicinal products based on genes, cells and 
tissues: Regulation (EC) No 1394/2007 on ‘ATMP’ 
(the ‘ATMP Regulation’). This was a new category of 
medicinal product established by the law, which cov-
ers many, though not all products deemed to be regen-
erative medicine products. The regulation established 
an EU-wide centralized system for market approval 
applicable to products either ‘prepared industrially’ 
or ‘manufactured by a method involving an industrial 
process’. The safety standards differ somewhat from 
the accepted pharmaceutical regime, partly because of 
the novel modes of action of regenerative products and 
the need to take account of aspects such as potency; 
the regulators continually emphasize that producers 
should consult them at an early stage. The ‘indus-
trial’ definition implied that some therapies would be 
allowed to be produced outside the conventional phar-
maceutical batch production, and thus the famous, if 
not by now infamous, ‘hospital exemption’ was cre-
ated. This exemption means that medicinal products 
not falling under centralized EU regulation are not to 
be regulated as part of the harmonized regime across 
the EU marketplace, though they have to respect 
national laws [13] and should maintain the same level of 
technical and safety standards.
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The industrial/nonindustrial distinction is crucial 
to defining the status and responsibilities of producers 
of regenerative products, whether in hospitals or in the 
commercial sector. Here we see an attempt to define a 
borderline between commodity market and nonmar-
ket forms of the production of tissue and cell therapy, 
typically, though not straightforwardly, institutional-
ized in the distinction between hospitals and commer-
cial enterprises (and leaving aside such difficult issues 
as the fact that there is no legal definition of a ‘hospi-
tal’ in EU law, and that the legal entities which consti-
tute healthcare providers vary greatly across the EU). 
Thus the hospital exemption has emerged as an alter-
native, national-level gateway to clinical application, 
requiring in the UK the regulator MHRA approval 
of a manufacturing license, but is widely acknowl-
edged to be one of the most controversial features of 
the regulation and its implementation in different EU 
member states. The guidance provided by national 
authorities on application of the hospital exemption 
varies greatly across different member states, par-
ticularly revolving around the number of individual 
therapeutic applications of the ‘same’ procedure that 
are regarded as breaking the ‘nonindustrial’ rule and 
amounting to a ‘routine’ service. In the UK, the hos-
pital exemption has only been granted to a minimal 
number of manufacturing sites (data from a current 
research project indicate that the exact number is not 
clear, due to some producers possibly confusing the 
hospital exemption with the ‘specials’ scheme [15] (and 
see below). It is possible that the low uptake in the UK 
is because most clinical applications to date involve 
transport of materials across national borders, which is 
not allowed under that scheme – unlike the ‘specials’ 
scheme. It is clear that some developers/producers see 
this exemption as an attractive option, and the EMA 
has expressed concern that the exemption not be over-
used in terms of numbers of individual patient appli-
cations – thus distorting the marketplace for commer-
cialized products – nor that member states fail to apply 
analogous safety criteria to the production processes 
and resulting therapies. EMA’s concern includes both 
market distortion and the safety regarding, especially, 
stem cell products [15].
Alongside the hospital exemption, the UK had previ-
ously created a pharmaceuticals ‘specials’ scheme under 
2001 EU pharmaceuticals legislation which provides: 
“a member state may, in accordance with legislation in 
force and to fulfill special needs, exclude from the pro-
visions of this (medicines) Directive medicinal products 
supplied in response to a bona fide unsolicited order, 
formulated in accordance with the specifications of an 
authorized healthcare professional and for use by an 
individual patient under his direct personal responsibil-
ity.” For such products, no product license or marketing 
authorization is required, but a manufacturer’s (GMP 
standards) license is required. Under this scheme, doc-
tors and certain other prescribers can commission an 
unlicensed relevant medicinal product to meet the spe-
cial needs of individual patients [13]. It is known in the 
UK that this gateway is favored by producers, compared 
with the ATMP hospital exemption.
Another alternative to the obligatory gateway of 
centralized pharmaceutical/ATMP gatekeeping is, 
arguably, designation of a new cell technology as a 
medical device. This is generally seen by developers 
as a less stringent route in Europe for RM products, 
compared with the pharmaceutical route and a num-
ber of products under development and a few on the 
market are regulated in this way. In the EU, medical 
device market assessment is made by devolved ‘noti-
fied bodies’ which are specialist centers with particu-
lar expertise in different types of devices, mandated 
under the EU Medical Device Directives. Products 
are given a classification according to the deemed level 
of physical health risk. Device status can be a realistic 
and crucial consideration for developers, because the 
‘primary mode of action’ of given technologies is by 
no means always clear-cut, and indeed is one of the 
aspects that regulators such as the EMA’s Committee 
for Advanced Therapies regularly adjudicates on. Thus 
for example the rise of ‘closed system’ centrifuge tech-
nologies in which a patient’s cells are processed within 
a single operative procedure to isolate ‘regenerative 
cells’ (e.g., producers Cytori; Regeneus), which may 
include adult/mesenchymal stem cells, are regulated as 
medical devices, and the resultant therapy is not sub-
ject to regulation because it is assessed as not involving 
‘substantial manipulation’, one of the key criteria for 
defining an ATMP product.
So there are a range of developments in gatekeeping 
policy designed to allow potentially beneficial innova-
tive technologies to pass through one or other gateway 
to market, to a greater or lesser degree, under various 
conditions and in some cases prior to full marketing 
authorization. As has been noted, some of these are 
mandated within legal/regulatory frameworks, while 
others are not.
Gateways to healthcare system & clinical 
adoption
This section considers the policy development and 
activity of recent discussions and developments in 
the MHRA, NICE and NHS England and high-level 
Regenerative Medicine Expert Group (RMEG) meet-
ings during 2014 (in which the author participated), 
which was formed on the recommendation of a 2013 
House of Lords Science and Technology Committee 
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report on RM. The RMEG was a multistakeholder 
group charged with producing recommendations on 
the sector for the UK government to consider. Again, 
the focus in this section is on the relaxative exceptions 
and exemptions that appear to be being debated and 
created in and around gateways through which pro-
ducers and their products must pass. These apparent 
relaxations are under negotiation and debate, so points 
of expert disagreement, contested positions, interests 
and methodologies are highlighted.
In the UK, one of the schemes now being embraced 
under the holistic lifespan Medicines Adaptive Path-
ways to Patients (MAPPS) concept referred to above 
is the ‘Early Access to Medicines Scheme’ [16], which 
was instigated in the UK government’s 2011 new 
strategy for life sciences. This scheme “aims to give 
patients with life threatening or seriously debilitating 
conditions access to medicines that do not yet have a 
marketing authorization when there is a clear unmet 
medical need,” and allows for designation as a promis-
ing innovative medicine (PIM). A PIM will: “…give an 
indication that a product may be eligible for the Early 
Access to Medicines Scheme (based on early clinical 
data). The PIM designation will be issued after an 
MHRA scientific meeting and could be given several 
years before the product is licensed” [16].
Regenerative medicine products are within the 
scope of the scheme: as the MHRA website pro-
claimed in November 2014: “MHRA awarded the 
first PIM designation for a cell therapy product for 
the treatment of cancer on 8 September 2014.” The 
scheme is distinct from the legal licensing flexibilities 
discussed above which operate within existing market 
authorization law, and mandates the producer to pro-
vide the therapy outside the marketplace, at no cost 
until licensing is achieved. The EAM scheme has been 
supported by the British government in consultation 
with trade associations and other interested parties 
during 2014, in response to earlier stakeholder consul-
tations by MHRA and the Department of Health [17]. 
The scheme explicitly addresses “the landscape for 
early access to medicines which reflects the UK Life 
Sciences Strategy and NHS Innovation Health and 
Wealth reforms,” and “reflects the profound changes 
driven by Genomics, Data, and the rise of stratified 
and personalized medicines” [17]. Notably also, patient 
group involvement is explicitly recognized in the early 
adoption process, as it is in the MAPPS philosophy: 
“encourages startups, patient groups and charities to 
collaborate within the extensive infrastructure via the 
National Institute for Health Research funded Clini-
cal Research Facilities and Biomedical Research Cen-
tres and Units in leading NHS Trust/university part-
nerships” [17]. The government response also mandates 
for “a newly coordinated NICE technology appraisal 
and NHS England Commissioning process.”
The first product to be accorded full EAM status 
via positive scientific opinion was announced in early 
2015: pembrolizumab, a monoclonal antibody pro-
duced by US company Merck (NJ, USA). The data 
requirements for the Early Access to Medicines Scheme 
are less onerous than the full marketing authorization 
application dossier which would otherwise be required: 
“the trigger for an Early Access to Medicines scientific 
opinion does not necessarily have to be the submission 
of a dossier for marketing authorization application, 
but the availability of a sufficiently compelling case 
based on the total data and evidence collected to date 
as assessed by the MHRA” [16].
While the Early Access Scheme is operated by the 
market-entry gatekeeper the MHRA, it requires coor-
dination with NICE and NHS England as the com-
missioner of health services, including especially ‘spe-
cialized services’ [18]. NHSE’s Specialized Services’ 
strategy is to have a “clear focus on a range of rare con-
ditions and low volume treatments ranging from medi-
cal genetics, kidney disorders and uncommon cancers 
to complex cardiac interventions, burn care and some 
specialized services for children” [18]. The rationale for 
this set of services is thus to provide services for rela-
tively rare medical conditions with severe effects, and 
thus does apply in principle to some regenerative prod-
ucts. Likewise, the NHSE has to produce a policy for 
a new technology if five or more mandated ‘Individual 
Patient Funding Requests’ are received from NHS cli-
nicians, so this also may apply to regenerative medicine 
products.
Alongside NICE, as national commissioner of 
health services NHS England undertakes some tech-
nology assessments that NICE does not undertake, and 
contracts with providers in order to secure services for 
the population, including the aforementioned ‘special-
ized services’. The RMEG report to the UK govern-
ment discusses pros and cons of risk-sharing schemes 
between NHSE and local commissioners and com-
mercial technology providers, noting their drawbacks 
and refers more positively to NHSE’s recent ‘Commis-
sioning through Evaluation’ scheme, which is applied 
to a limited number of therapies, and which enables 
health technology assessment (HTA) assessment to 
be undertaken while a technology is introduced in a 
limited number of sites. The RMEG concludes on this 
issue with a very general, flexible recommendation, 
simply that ‘an innovative business model’ should be 
developed [19].
NHSE had set up a working group on regenerative 
medicine in response to the House of Lords report. The 
following recommendation also is made in the RMEG 
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report, to strengthen this cross-cutting initiative: “the 
cross Clinical Reference Group (CRG) working group 
for regenerative medicine set up by NHS England to 
support RMEG should be further developed into a for-
mal ‘CRG for regenerative medicine’. It should include 
clinicians covering a wide range of specialisms and 
experience in regenerative medicine to provide specific 
insight and advice on regenerative medicine products 
to other CRGs and NHS England” [19].
Another possible relaxation, arguably, could be 
achieved via ‘value-based pricing’ and ‘value-based 
assessment’ (VbA). Several countries have been devel-
oping frameworks under these names to try to define 
the health and health system value of drugs in broader 
ways than hitherto. In the UK this is a methodologi-
cal HTA/NICE development. The concept arguably 
extends the possibilities for RM products becoming 
adopted in the NHS, especially because many of these 
products promise long-term benefits, that may not eas-
ily be captured by existing methodologies. VbA has 
been partially developed by NICE following extensive 
consultation, highlighting a high degree of uncer-
tainty around the definition of the concept. It is cur-
rently unclear if and how this might be incorporated 
into NICE’s assessment methodologies and organiza-
tional infrastructure, and how closely it will be tied to, 
or equated to, the long-established QALY methodol-
ogy [20]. In a former incarnation, the intention was to 
develop value-based pricing, whose three dimensions 
for methodological development were defined as: ‘bur-
den of illness’, ‘therapeutic improvement’ and ‘wider 
societal benefits’: “…we intend to consider the wider 
impact of a disease on people’s ability to be part of soci-
ety. We refer to this as the ‘wider societal impact’ and 
define it as the loss (or shortfall) in a person’s capac-
ity to engage with society as a result of living with the 
disease or condition, compared with their capacity to 
engage with society without the condition. We propose 
calculating wider societal impact by measuring the 
absolute shortfall in QALYs” [20].
The tension between existing methodology and 
the new proposals is evident here (in the proposal to 
retain the QALY method as the basis for wider societal 
impact assessment rather than population health status 
and longevity). Attempting to reinforce the extension 
of QALYs, later in the document we see: “since loss 
of good health affects a person’s ability to engage in 
society, societal shortfall can be assessed by measur-
ing the absolute QALY loss” [20]. Nevertheless, if this 
methodological innovation is implemented, it will 
imply a widening of the goal-posts or oiling of the 
hinges of the gateway controlling products’ entry into 
the UK healthcare marketplace, by extending the cri-
teria of assessment. In principle VbA thus means that 
a broader, social-good-oriented approach to valuing 
technologies could be used, an example, crudely speak-
ing, being the inclusion in gatekeeping evaluations of 
potential knock-on effects of a technology on return to 
work of previously incapacitated patients, with its con-
sequent calculable impact on the economy. An early 
analysis comparing extended US data that included 
some societal ‘value’ elements with existing standards 
of care, produced positive conclusions for a value-based 
approach for a number of conditions [21]. However, the 
development of VbA has stalled on this point at the 
time of writing, under criticism that it would operate 
in an ageist way, favoring for example, formal eco-
nomic activity over informal caring for example, and 
lack of public support for an ‘innovation premium’ [22].
Negotiating the gateways
The potential for tensions and potential nonalign-
ment between the two forms of gatekeeping described 
above is high, and some recent initiatives are hybrids, 
straddling the boundary between gateways to market 
and gateways to reimbursement, attempting to bridge 
between these two gatekeeping arenas. The range of 
potential gateways is outlined in Box 1.
When it comes to the pathway taken by specific 
regenerative medical products, there is often likely to be 
iteration between the market and HTA/reimbursement 
parts of the translational journey. There are examples 
of market-authorized products with regenerative 
claims that have not been authorized by national HTA 
bodies, and, short of HTA-negative opinions, there 
are examples of national HTA processes resulting in 
requests to a manufacturer of a cell therapy product to 
undertake more research to address particular infor-
mation deficits. An example of this decisional route 
in NICE’s deliberations is ‘ReCell®’, a spray form cell-
based product for burn injuries: “The medical tech-
nology guidance on the ReCell Spray-On Skin system 
for treating skin loss, scarring and depigmentation 
after burn injury recommends further research. This 
recommendation is not intended to preclude the use 
of the technology in the NHS but to identify further 
evidence” [23]. Such policy positions clearly attempt to 
find a balance between commercial interests, clinician 
decision-making and national system-level evidence 
appraisal, attempting to find a ‘third way’ through the 
market and HTA gateways.
Likewise, there are escalating calls for increas-
ing dialogue between market regulators and HTA/
reimbursement assessors and payers more widely in 
regenerative medicine communities. In the UK, there 
are currently moves to create closer coordination 
between NICE and the MHRA and between NICE 
and NHS England. Links between the two gatekeep-
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ing arenas that are discussed here may be increasing 
more in some jurisdictions than others. In fact the 
EMA since 2010 has offered parallel scientific advice 
with HTA bodies to attempt to allow medicine devel-
opers to establish the required evidence base. A draft 
best practice guidance for EMA–HTA parallel scien-
tific advice was published for public consultation in 
May 2014 [24].
In considering the fundamental tension between 
the gateway requirements for market approval and 
reimbursement decisions, we can note that the ‘adap-
tive pathways’ pilot project of EMA explicitly involves 
early negotiation between EMA and HTA bodies in 
attempting to engineer a life cycle approach. It thus 
aligns, in spirit at least with the ‘early access’ scheme 
in the UK. Clearly, the shared aim is to achieve con-
ditional forms of availability of innovative medicines 
in the two gatekeeping arenas. The different gateways 
discussed here are categorized and listed in Box 1.
Discussion
Many of the pressures apparent in the UK case are 
echoed currently in the global context in which regen-
erative medicine is being developed. The tension seen 
in cases of disjunction between market authorization 
gatekeeping and healthcare adoption gatekeeping is 
starkly exemplified by the South Korean case. This 
nation has been progressive with RM approval, hav-
ing approved 16 therapies to 2014 – said to be the 
most of any country in the world – but has not sup-
ported these same technologies through reimburse-
ment decisions. Not one has been reimbursed or 
exported out of the country [25]. On the other hand, 
a precedent in attempts to ease this alignment and 
reduce the tension can now be found with Japan’s 
well-known recent regulatory innovation, where the 
government has implemented a conditional approval 
system. Cell therapy developers are only required to 
have a single, albeit larger than conventional, Phase I 
study, sufficient to demonstrate stringently a prod-
uct’s safety, to achieve initial marketing approval. 
Notably, although few in number, all the cell thera-
pies currently approved in Japan, have been approved 
for reimbursement, the converse of South Korea. 
However, although Japan’s new system may stimulate 
private investment, this may not accelerate the rate of 
products reaching the marketplace and clinical prac-
tice, because only products with more or less guaran-
teed reimbursement will be proposed and receive this 
approval.
Governments worldwide are gripped by an innova-
tion fever when it comes to bioscience and biotechnol-
ogy, and the UK government’s current ‘Accelerated 
Access Review’ (AAR) [26] is a good example of this. 
While the discussion in this perspective has focused 
on existing gatekeeping flexibilities, the AAR interim 
report affords a glimpse of what direction future policy 
developments, many applicable to regenerative medi-
cine, might take. While some coordinative develop-
ments between the different gateways of approval are 
already under way, the AAR consultation emphasizes 
that this issue remains at the forefront of stakeholder’ 
concerns, reflected in its ‘key messages’: “ensuring con-
sistency of requirements across regulatory and com-
missioning components of the pathway;” and “align-
ing regulatory and reimbursement requirements and 
the data requirements between agencies internationally 
and nationally” [26]. The interim AAR report also high-
lights stakeholders’ perception that the reimbursement 
process can be improved through greater flexibility 
and conditional adoption, echoing the flexible adop-
tion gateway features discussed above. The interim 
report highlights stakeholders concerns of “assessing 
value based on factors other than cost–effectiveness; 
Having a more flexible and speedy appraisals process 
Box 1. Gateways to market and clinic applicable 
to regenerative medicine in the UK.
Mainstream gatekeeping regimes: central, legal
•	 EU Pharmaceutical directives
•	 EU Advanced Therapy Medicinal Products 
Regulation; UK Medicines and Healthcare products 
Regulatory Authority implementation and guidance;
•	 National Health Technology Assessment/NICE
Exceptions & exemptions: multiple; flexible; 
alternative
•	 Market and individual patient gateways:
 – Adaptive licensing
 – Exceptional circumstances
 – Advanced therapy medicinal products hospital 
exemption
 – Accelerated assessment
 – ’Specials’ license (UK only)
 – Orphan designation
 – Medical device
•	 Hybrids: integration/legal easing/broadening 
criteria:
 – Adaptive pathways (lifespan approach)
 – Early Access Scheme/promising innovative 
medicine assessment
 – Conditional approval
 – Risk-sharing reimbursement
 – Value-based pricing/assessment (if implemented)
•	 Adoption gateways:
 – Commissioning through Evaluation – National 
Health Service Executive
 – National Health Service Executive special 
commissioning schemes
 – Local devolved commissioning
 – Multiple individual patient funding requests
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that allows for different types of evidence, conditional 
approvals and varying criteria for different categories 
of products” [26].
As part of the AAR, RAND Europe was commis-
sioned to produce a study focusing on leading exem-
plars internationally of speeding up adoption, which 
reported in mid-2015 [27]. Although concluding that 
one-size-fits-all examples do not exist, this study pro-
duced ‘four conceptual approaches’ categorizing key 
interventions to speed up adoption, namely: “pro-
cess improvement, risk sharing, process linkage and 
addressing market failure/pricing” [27]. In turn, these 
approaches typically would involve: reducing the time 
taken in a stage of the process by extra funding among 
others; ‘blurring decision points’ by spreading risk; 
reducing duplication; and addressing pricing for exam-
ple by broadening cost–effectiveness or value proposi-
tion criteria. As the RAND report points out, different 
approaches to the gateways to market and clinic may 
be combined. For example, the concept of value-based 
pricing in principle may combine elements of risk-
sharing (conditional, performance-related reimburse-
ment) and broadened socioeconomic/health value cri-
teria (pricing), along with ongoing data collection and 
evidence feedback. An evaluation from Sweden sug-
gests that such a multipronged scheme may well speed 
up the adoption of innovative medicines [28].
The AAR report can be read as supporting the devel-
opment in the UK of market access and adoption flexibil-
ities along the lines of the embryonic schemes discussed 
above, and some of which are already introduced to some 
extent elsewhere in the world. A number of examples 
of other such gateway innovations, not available in the 
UK/EU (and not listed in Box 1), could be mentioned 
as possible future developments. These include ‘paral-
lel review’, similar in principle to the scheme of EMA’s 
adaptive pathways pilot, overlapping HTA assessment for 
reimbursement with the market authorization process, 
which has already been introduced by Health Canada 
and the Canadian Agency for Drugs and Technologies 
in Health for all new drugs in late 2012.
Are the developments considered in this paper really 
about gatekeeping after the cattle have already broken 
down the fences? In other words, are there now so 
many schemes for exceptions and exemptions or alter-
native gateways to the dominant gatekeeping institu-
tions and methodologies – in principle at least, or in 
terms of visionary scenarios of medical futures – that 
the slowly growing tide of novel RM technologies is 
clearly going to be well supported, strongly evidence-
based and sustainable long term? This survey of current 
flexibilities suggests that this is not the case. Although, 
as this paper shows, there are a number of apparent 
easings and relaxations of the prevailing regimes, vari-
ous exceptions and exemptions and alternate gateways, 
their scope (in the UK at least) is somewhat limited, 
in spite of the examples of early conditional authoriza-
tion and the like. This limited scope of exceptions and 
exemptions is defined by narrow criteria of rare disease, 
orphan designation, compassionate use, critical disease 
applications such as cancer, emergency or unmet need 
and individual medical prescription. Although there is 
a case for compassionate use aligning with the ‘enlight-
ened self-interest’ of pharmaceutical developers, and 
that human rights and disability legislation should 
require reimbursement of orphan medicine costs, it 
remains the case that they present a number of chal-
lenges, not least in the UK’s case where there is no 
formal compassionate use program [12].
Furthermore, more than one outcome analysis sug-
gests that with conditional approval, actual approval 
times are not necessarily shortened. Thus accelerated 
approval systems may not actually result in incentiviza-
tion and faster approval times [29]. Likewise, evidence-
based doubt has been cast on the maintenance of efficacy 
standards for pharmaceuticals under both the European 
conditional marketing and the US (FDA) accelerated 
approval in the case of cancer drugs [30]. Hence, at 
the very least, the effects of these exceptions and con-
ditional contracts on producers’ innovation pathways 
and approved/adopted product volumes and timescales, 
and the implications for safety and efficacy standards, 
requires further, thorough and systematic evaluation.
A current social science research project [14] is assess-
ing the dynamics of regenerative medicine adoption in 
detail in the UK case, assessing business models and the 
‘readiness’ of the UK health system as a set of economic, 
biomedical and healthcare infrastructures. Such disci-
plines have a role to play here, and this project builds 
on novel approaches that are required to understand the 
broader social and economic environment into which 
regenerative medicine products will be more, or less, 
adopted. Surrounding the more or less formal gateways 
of access to new products is a web of perceived values 
and attributes of new health products, which gradually 
evolves, is promoted and contested by stakeholders, and 
percolates through to the world view of policymakers 
and decision makers. ‘Technology identities’ are built 
up through these processes [31] and influence the passage 
of products through the market and health system gate-
ways described here. Such research also enables us to see 
the many ways in which regenerative medicine products 
share characteristics, as innovations-in-context, with 
other medical technology innovations [32].
Conclusion
In summary, a range of alternative gateways to the 
marketplace and to healthcare adoption of regenera-
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tive medicine products appear, slowly and with a high 
degree of gatekeeper attention, to be proliferating.
Future perspective
It is likely that the trends noted here in alternative 
gateways will increase, both in the volume of prod-
ucts and in the range of different schemes at the 
borderline between market authorization and reim-
bursement gateways (that is, the ‘Hybrids’ section in 
Box 1). Serious questions about the market incentiv-
ization and the overall public health benefit of these 
developments remain, with the few already published 
outcome evaluations being inconsistent in their sup-
port for gatekeeping flexibilities. Policy perspectives 
focused narrowly on supply-side innovation and 
acceleration, albeit in the name of ‘patient access’ run 
a risk of side-lining system-level analysis of the true 
value, social consequences and public health effects of 
these developments. It is also unclear as yet whether 
highly innovative, possibly game-changing prod-
ucts will be facilitated by the emerging gateways and 
their flexibilities. These evolving measures therefore 
require rigorous systematic evaluation of their impli-
cations for the advancement of regenerative medicine 
and also for population-level access to its potential 
benefits.
Financial & competing interests disclosure
The author has no relevant affiliations or financial  involve-
ment with any organization or entity with a financial interest 
in  or  financial  conflict  with  the  subject  matter  or  materi-
als discussed in the manuscript. This includes employment, 
consultancies,  honoraria,  stock  ownership  or  options,  ex-
pert  testimony,  grants  or  patents  received  or  pending,  or 
royalties.
No writing assistance was utilized in the production of this 
manuscript.
Open access
This  work  is  licensed  under  the  Creative  Commons  Attribu-
tion  4.0  License.  To  view  a  copy  of  this  license,  visit  http://
creativecommons.org/licenses/by/4.0/
Executive summary
•	 A range of regulatory and reimbursement flexibilities are developing that are important for regenerative 
medicine translation and for certain groups of patients.
•	 Developments in the UK are mirroring and in some cases leading broader international trends.
Gateways to market
•	 A range of exception-based licensing routes are available in the EU pharmaceutical regime, many of which are 
linked to orphan drug designation and compassionate use frameworks:
 – The UK has not adopted a formal compassionate use framework.
•	 The ‘hospital exemption’, within the advanced therapy medicinal product regime in the EU, is controversial 
and currently little used in the UK.
Gateways to clinic & healthcare system
•	 A range of conditional, risk-sharing and criteria-expanding approaches are being debated and experimented 
with.
•	 Notable developments are underway in the UK and EU to close the gap between market access regulation and 
adoption/reimbursement data requirements and Health Technology Assessment gatekeeping regimes.
Conclusion
•	 The current impact on speed of authorization and clinical translation of the available gateway flexibilities and 
measures to accelerate access should not be overestimated.
•	 Social science approaches are needed to set innovative medicines translational issues in context.
•	 The emerging gateway flexibilities should be evaluated for their effects on regenerative medicine 
development, safety and impact on population-level healthcare delivery.
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